


# SAMRC InfoSpace

## Distinct inflammatory mediator patterns in young black and white adults: The African-predict study

Item Type	Article
Authors	Crouch, S.H;Botha-Le Roux, S;Delles, C;Graham, L.A;Schutte, A.E
Citation	Crouch SH, Roux SB, Delles C, Graham LA, Schutte AE. Distinct inflammatory mediator patterns in young black and white adults: The African-predict study. Cytokine. 2020 Feb;126:154894. doi: 10.1016/j.cyto.2019.154894.
Publisher	Elsevier
Journal	Cytokine
Rights	Attribution 3.0 United States
Download date	2026-04-19 11:25:53
Item License	<a href="http://creativecommons.org/licenses/by/3.0/us/">http://creativecommons.org/licenses/by/3.0/us/</a>
Link to Item	<a href="https://doi.org/10.1016/j.cyto.2019.154894">https://doi.org/10.1016/j.cyto.2019.154894</a>



## Distinct inflammatory mediator patterns in young black and white adults: The African-predict study



Simone H. Crouch<sup>a</sup>, Shani Botha-Le Roux<sup>a,b</sup>, Christian Delles<sup>c</sup>, Lesley A. Graham<sup>c</sup>, Aletta E. Schutte<sup>a,b,\*</sup>

<sup>a</sup> Hypertension in Africa Research Team (HART), North-West University, Potchefstroom, South Africa

<sup>b</sup> MRC Research Unit: Hypertension and Cardiovascular Disease, North-West University, Potchefstroom, South Africa

<sup>c</sup> Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom

### ARTICLE INFO

#### Keywords:

Inflammatory mediators  
Inflammation  
Ethnicity  
Blood pressure

### ABSTRACT

**Objective:** Inflammatory mediators have been implicated in the early stages of cardiovascular disease development, including hypertension. Since global reports reflect a higher hypertension prevalence in black than white populations, we hypothesise the involvement of specific inflammatory mediators. We therefore compared a detailed range of 22 inflammatory mediators between young black and white adults, and determined the relationship with blood pressure.

**Approach and results:** We included 1197 adults (20–30 years; 50% black; 52% female) with detailed ambulatory blood pressures. Blood samples were analysed for 22 inflammatory mediators. For pro-inflammatory mediators, the black adults had higher C-reactive protein, interferon-inducible T-cell alpha chemoattractant, macrophage inflammatory protein 3 alpha (all  $p \leq 0.008$ ), but lower interferon-gamma, interleukin (IL)-1 $\beta$ , IL-8, IL-12, IL-17A, and tumour necrosis factor alpha (all  $p \leq 0.048$ ). For anti-inflammatory mediators the black group consistently had lower levels (IL-5, IL-10 and IL-13 (all  $p \leq 0.012$ )), resulting in generally higher pro-to-anti-inflammatory ratios in black than white adults ( $p \leq 0.001$ ). In mediators with pro- and anti-inflammatory functions, the black group had lower granulocyte-macrophage colony-stimulating factor and IL-6 (both  $p \leq 0.010$ ). These patterns were confirmed after adjustment for age, sex and waist circumference, or when stratifying by hypertensive status, sex and socio-economic status. Multi-variable adjusted regression analyses and factor analysis yielded no relationship between inflammatory mediators and blood pressure in this young healthy population.

**Conclusions:** Black and white ethnic groups each consistently presented with unique inflammatory mediator patterns regardless of blood pressure, sex or social class. No association with blood pressure was seen in either of the groups.

### 1. Introduction

Inflammatory mediators have been implicated in the development of chronic diseases [1–3], including hypertension and cardiovascular disease (CVD) [4]. However, the physiological mechanisms through which this occur, are not all completely understood [5–9]. A number of pro-inflammatory mediators, such as CRP [10], IL-6 [10–12], IL-17A [12,13], and TNF- $\alpha$ , [12] contribute to an increase in blood pressure. In

contrast, others such as IL-10, GM-CSF and IFN- $\gamma$  show inverse associations with blood pressure [12,14]. The functions of numerous other pro- and anti-inflammatory mediators such as IL-21 [15], and ITAC [16] are not yet clearly known, and neither is their association with blood pressure and CVD. Pro- and anti-inflammatory mediators are mainly produced by helper T cells and macrophages but also by other cell populations such as monocytes and certain nonimmune cells [17].

Globally it has been reported that black populations have higher

**Abbreviations:** CVD, Cardiovascular disease; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; GM-CSF, Granulocyte-macrophage colony-stimulating factor; IFN- $\gamma$ , Interferon gamma; IL-1  $\beta$ , Interleukin 1 beta; IL-2, Interleukin 2; IL-4, Interleukin 4; IL-5, Interleukin 5; IL-6, Interleukin 6; IL-8, Interleukin 8; IL-10, Interleukin 10; IL-12, Interleukin 12; IL-13, Interleukin 13; IL-17A, Interleukin 17A; IL-23, Interleukin 23; ITAC, Interferon-inducible T-cell alpha chemoattractant; MIP-1 $\alpha$ , Macrophage inflammatory protein 1-alpha; MIP-1 $\beta$ , Macrophage inflammatory protein 1-beta; MIP-3 $\alpha$ , Macrophage inflammatory protein 3-alpha; TNF $\alpha$ , Tumour Necrosis Factor Alpha

\* Corresponding author at: Hypertension in Africa Research Team (HART), North-West University, Private Bag X1290, Potchefstroom 2520, South Africa.

E-mail address: [Alta.Schutte@nwu.ac.za](mailto:Alta.Schutte@nwu.ac.za) (A.E. Schutte).

<https://doi.org/10.1016/j.cyto.2019.154894>

Received 19 July 2019; Received in revised form 1 October 2019; Accepted 17 October 2019

Available online 24 October 2019

1043-4666/ © 2019 Elsevier Ltd. All rights reserved.

blood pressure than white populations [18,19]. Many mechanisms have been proposed to explain this, such as a suppressed renin-angiotensin-aldosterone-system and salt sensitivity in black populations [20–22]. Based on our previous work in South Africa [23,24], another possible mechanism could be related to inflammation. Differences in pro- and anti-inflammatory mediator concentrations between ethnic groups have indeed been reported, e.g. in populations of African, European and South American descent [24–30]. Findings remain contradictory [29]; for example Mwantembe et al. [25] found that IL-1 $\beta$  levels were higher in black than in white adults, whereas Albandar et al. [27] found levels to be highest in Hispanics, followed by white individuals, while black participants exhibited the lowest levels. With regards to IL-6, Hong et al. [31] reported no ethnic differences between black and white participants, while Elkind et al. [26] found black individuals to have higher levels than white individuals. In South Africa, it was consistently shown that black individuals display higher levels of pro-inflammatory markers than whites [23,24,32].

In this study we therefore compared a detailed range of 22 pro- and anti-inflammatory mediators and numerous blood pressure measurements between young black and white adults. We also investigated the relationships between blood pressure and the pro- and anti-inflammatory mediator profile. This unique young disease-free sample allowed us to examine ethnic differences without interference from overt cardiovascular disease.

## 2. Methodology

### 2.1. Study population

This study forms part of the African Prospective study on the Early Detection and Identification of Cardiovascular disease and Hypertension (African-PREDICT) [33]. We recruited young black and white, men and women, between the ages of 20–30 years. African-PREDICT included apparently healthy individuals who were HIV uninfected; had a screening office brachial blood pressure of < 140 mmHg systolic and < 90 mmHg diastolic; had no self-reported previous diagnosis or used any medication for a chronic disease; and, if female, were not currently pregnant or lactating. Although individuals with office brachial BP of  $\geq 140$  and/or  $\geq 90$  were excluded during screening, there was an average two-week period between the screening and research phases. Some participants were classified as being hypertensive based on 24hr ambulatory blood pressure during the research phase and were included in this study. This study analysed data for participants included in the baseline phase of the study ( $n = 1202$ ). Participants on anti-inflammatory medication or with missing biochemical analyses data were additionally excluded, resulting in a total population size of  $n = 1189$ . The study was approved by the Health Research Ethics Committee (HREC) of the North-West University (NWU-00058-18-A1), adheres to the Declaration of Helsinki and all participants in the study provided written informed consent prior to participation.

### 2.2. General measurements

Self-reported data with regards to demographic and lifestyle information were collected using a questionnaire. Socio-economic status was calculated using a point system that was adapted from Kuppuswamy's Socio-economic Status Scale [34] for a South African environment. Height, weight and waist circumference were measured using standard methods [33]. Body mass index (BMI) was calculated using weight (kg)/height(m)<sup>2</sup>. A compact, chest-worn accelerometric device (Actiheart4 CamNtech Ltd and CamNtech Inc, UK) was used to objectively measure physical activity over a maximum period of 7 days.

### 2.3. Blood pressure

#### 2.3.1. Brachial blood pressure

Duplicate brachial blood pressure measurements were done on the left and right arms, with a 5-minute interval in-between, in a seated and resting state. We used the Dinamap® Procare 200 Blood Pressure Monitor (GE Medical Systems, Milwaukee, WI, USA).

#### 2.3.2. Central blood pressure

cSBP was shown to provide a better estimate of cardiovascular mortality than other measures of blood pressure [35]. We therefore performed pulse wave analysis using the SphygmoCor XCEL (AtCor Medical, Sydney, Australia) device. This technique records the peripheral pressure waveforms and generates a corresponding central waveform [36].

#### 2.3.3. Ambulatory blood pressure

Participants were fitted with a validated 24-hour brachial ambulatory blood pressure (ABPM) monitor (Card(X)plore® CE120, Meditech, Budapest, Hungary). The apparatus was programmed to record every 30 min during the day (06 h00 to 22 h00) and every hour during the night (22 h00 to 06 h00).[37] Participants had a mean successful recording rate of 88%.

### 2.4. Biological sampling and biochemical analyses

Participants fasted overnight for at least eight hours prior to attending the day of research measurements. Blood samples were collected from the median cubital vein. The samples were prepared according to standardised protocols and stored at  $-80^{\circ}\text{C}$  until the time of analysis.

Serum samples were analysed for high-sensitivity C-reactive protein (CRP), total cholesterol, low- and high-density lipoprotein cholesterol, glucose and  $\gamma$ -glutamyltransferase (GGT) (Cobas Integra® 400plus, Roche, Basel, Switzerland). Serum creatinine concentrations were measured using the Creatinine Jaffé Gen.2 reagent (Roche, Basel, Switzerland). Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology (CKD-EPI) formula, without race in the equation as this is not appropriate for a South African population [38,39]. Serum cotinine was analysed using a chemiluminescence method on the Immulite (Siemens, Erlangen, Germany) apparatus. EDTA whole blood samples were analysed for white blood cell, neutrophil, basophil, eosinophil, lymphocyte and monocyte count (Coulter AcT5 diff OV Hematology analyzer, Beckman Coulter, Brea, CA, US).

A MILLIPEX Map Human High Sensitivity T Cell Magnetic Bead Panel (EMD Millipore, Merck, Missouri, USA) was used to analyse 21 cytokines. This multiplex panel was analysed using Luminex xMAP technology on the Luminex 200™ analyser. This technology performed immunoassays on the surface of fluorescent-coded magnetic beads known as MagPlex-C microspheres. Microspheres were colour-coded with two fluorescent dyes. Through precise concentrations of these dyes, distinctly coloured bead sets of 500 5.6  $\mu\text{m}$  polystyrene microspheres or 80 6.45  $\mu\text{m}$  magnetic microspheres were created, each of which was coated with a specific capture antibody. A biotinylated detection antibody was introduced, and the mixture was then incubated in a streptavidin-phycoerythrin (PE) conjugate reporter. The fluorescent intensity of the reporter was determined which correlates with the concentration of a given analyte in solution. A standard curve was generated to calculate final analyte concentration.

### 2.5. Statistical analyses

IBM®, SPSS® version 24 (IBM Corporation, Armonk, New York) was used for data analysis. GraphPad Prism 5.03 (GraphPad Software, San Diego) was used all for graphics. Continuous variables were inspected

for normality using QQ plots as well as inspection of skewness and kurtosis. Variables with non-Gaussian distributions were logarithmically transformed. To evaluate if data should be presented and analysed independently by sex or ethnicity, we investigated the interactions of these variables on the relationship between cSBP, 24hr systolic blood pressure (SBP) and the full range of pro- and anti-inflammatory mediators. We divided our groups by ethnicity based on the interactions found (Table S1). Pro- to anti-inflammatory ratios were calculated based on literature [40,41], and new ratios were suggested based on instances where pro-inflammatory mediators were higher and anti-inflammatory mediators were lower in the black and white groups. T-tests and Chi-square tests were used to compare the profiles of black and white participants. Analyses of covariance, adjusting for age; sex; and waist circumference, were used for ethnic comparisons of pro- and anti-inflammatory mediator concentrations. This was also done in normotensive and hypertensive groups, and groups categorised according to socio-economic status. The relationships between measures of blood pressure as the dependent variables and pro- and anti-inflammatory mediators as the main independent variables were explored using Pearson, partial and multiple regression analyses. Factor analyses were performed using the factor function of SPSS. Principal component analyses were used and factors with an eigenvalue  $> 1$  were retained. Varimax rotation was used to obtain independent interpretable factors. A factor loading of  $\geq 0.3$  was used to interpret the factor patterns. Double loading was handled by placing the variable in the factor with the strongest loading factor. Factor scores with a cumulative percentage of  $> 50$  were subsequently used for multiple regression analyses to determine the relationship between measures of blood pressure and factor scores.

### 3. Results

The general characteristics of the participants ( $n = 1202$ ) are shown in Table 1. The overall mean blood pressures of all participants were in the optimal blood pressure ranges [37]. Compared to the white group, black individuals had lower 24hr and night SBP readings (all  $p \leq 0.027$ ), but higher office diastolic blood pressure (DBP) ( $p < 0.001$ ) and central SBP ( $p < 0.001$ ). With regards to body composition, the black group had a lower BMI and waist circumference.

Black participants showed higher levels of the pro-inflammatory mediators CRP, ITAC, MIP3- $\alpha$  (all  $p \leq 0.008$ ), but lower levels of IFN- $\gamma$ , IL-1 $\beta$ , IL-8, IL-12, IL-17A, and TNF- $\alpha$  (all  $p \leq 0.048$ ). Regarding anti-inflammatory mediators, black individuals had lower levels of IL-5, IL-10 and IL-13 (all  $p \leq 0.012$ ). In terms of mediators that display both pro- and anti-inflammatory functions, we observed lower levels of both GM-CSF and IL-6 (all  $p \leq 0.010$ ) in the black group. Black participants generally had higher pro-to-anti-inflammatory ratios than their white counterparts ( $p \leq 0.001$ ). The black group exhibited lower white blood cell, neutrophil, monocyte, eosinophil and basophil counts (all  $p \leq 0.013$ ).

We also performed analyses of covariance comparing black and white individuals (Table 2), adjusting for age, sex and waist circumference. Findings were largely similar (Fig. 1).

Additionally, we compared ethnic groups, stratified by hypertensive status, sex and the middle socio-economic status group to account for the role these factors may play in determining inflammatory mediator status (Tables II–VI). Similar to the ethnic comparisons in the total group, nearly identical ethnic profiles were seen, independent of hypertension status, sex and socio-economic status. Fig. 1 summarises the pro- and anti-inflammatory mediator profiles of black and white groups based on Table 2 and Tables I–VI.

Multiple regression analyses were performed to determine whether blood pressure (24 hr SBP, 24hr DBP, cSBP and nighttime SBP) is related to pro- and anti-inflammatory mediator concentrations within each ethnic group. In our young, healthy populations, the multiple regression analyses yielded no consistent statistically significant results

(Figs. 2 and 3 and Figs. I–II).

Factor analyses were performed with the pro- and anti-inflammatory mediator data to determine factor scores (Tables VII–VIII). Factor scores were subsequently used for multiple regressions analyses to determine whether blood pressure (24 hr SBP, 24hr DBP, cSBP and nighttime SBP) is related to the pro- and anti-inflammatory mediator factors; this yielded no statistically significant results (Table X).

## 4. Discussion

Here we report distinct pro- and anti-inflammatory mediator patterns in young and healthy white and black adults, independent of sex, hypertension or socio-economic status. Black individuals consistently showed higher pro-to-anti-inflammatory ratios when compared to their white counterparts. This suggests that the pro- and anti-inflammatory mediator profiles in this young healthy cohort are likely to be ethnic-specific and independent of blood pressure, sex or socio-economic status. With respect to blood pressure profiles, we found no independent relationships between individual inflammatory mediators or inflammatory mediator patterns with blood pressure in either of the young ethnic groups.

### 4.1. Ethnic profiling

When examining the pro-to-anti-inflammatory mediator ratios, black adults consistently displayed higher ratios, even though they were leaner, had better lipid and glycaemic profiles, as well as lower immune cell counts. These results for mediator ratios were found, despite the black group having lower levels for six of the fifteen pro-inflammatory mediators compared to whites, and higher levels of only three of the fifteen mediators. It is the anti-inflammatory mediators where the black group displayed lower levels for three of the four mediators, which resulted in overall higher pro-to-anti-inflammatory ratios.

Literature regarding ethnic differences in cytokine concentrations remains inconsistent. Elkand et al. [26] and Schutte et al. [23,24] found CRP levels to be higher in black than in white populations, which is in line with our findings. However, Ford et al. [42] found no difference in CRP levels between African-American and white children and young adults.

Many studies and systematic reviews focussed on only a few inflammatory mediators at a time, and usually the same mediators, such as CRP, IL-6, TNF- $\alpha$  and IL-1 $\beta$  [23,24,29,43–46]. This simplifies comparison between studies. In our study, we made use of a large range of mediators which, while complex, provides a better overall inflammatory profile.

One possible explanation for the ethnic-specific mediator profiles may be the differences in gene polymorphisms distribution across different ethnic groups [47]. It has been shown that differences in the inheritance of IL-6 and IL-10 genotypes in black populations result in higher expression when compared to white populations [47]. Differences in genotypes between black and white populations have also been seen where IL-2 is concerned [48].

Fifty-nine percent of the black population (versus 20% in whites) falls within a low socio-economic category. It has recently been shown that childhood environment may play a role in the development of inflammatory phenotypes suggesting that the overall low socio-economic status of this black population may play a role [49].

The effect of potential confounders on the difference in mediator concentrations should be taken into consideration. In our comparisons (Fig. 1) we adjusted for age, sex and abdominal obesity. Yet tobacco use [50], alcohol consumption [51], and obesity [52], which are often linked to socio-economic status [53–55], may play a role in increasing pro-inflammatory mediator levels, as studies have found that those with a low socio-economic status show elevated systemic inflammation [56,57]. However, when counteracting this by comparing black and

**Table 1**  
Characteristics of young black and white adults.

	Black (n = 599)	White (n = 590)	P
Age, years	24.5 ± 3.17	24.6 ± 3.06	0.55
Male, n (%)	296 (49.0)	281 (47.4)	0.58
<b>Socio-economic Status</b>			
Low, n (%)	356 (58.9)	118 (19.9)	< 0.001
Middle, n (%)	163 (27.0)	182 (30.7)	
High, n (%)	85 (14.1)	293 (49.4)	
<b>Office BP (mmHg)</b>			
Brachial SBP	117 ± 12.0	116 ± 12.6	0.16
Brachial DBP	79.4 ± 8.37	77.7 ± 8.12	< 0.001
Central SBP	110 ± 9.58	105 ± 9.69	< 0.001
<b>Ambulatory BP (mmHg)</b>			
24 h SBP	116 ± 8.99	118 ± 9.82	< 0.001
24 h DBP	68.8 ± 5.93	68.5 ± 5.86	0.45
Night SBP	107 ± 10.1	109 ± 10.9	0.027
Night DBP	59.6 ± 6.77	59.1 ± 6.70	0.14
Hypertensive status, n (%)	50 (8.40)	78 (13.2)	0.009
<b>Body Composition</b>			
Body mass index (kg/m <sup>2</sup> )	24.0 (17.6; 35.3)	25.0 (18.8; 35.1)	< 0.001
Waist circumference (cm)	77.0 (63.0; 97.0)	81.5 (64.9; 107)	< 0.001
	75.9 (64.3; 92.3)	88.5 (74.0; 110)	0.007
	78.2 (62.0; 102)	75.7 (63.5; 99.5)	< 0.001
<b>Inflammatory Markers</b>			
<i>Pro-Inflammatory</i>			
CRP (mg/L)	1.01 (0.09; 11.1)	0.78 (0.08; 7.89)	0.002
Fractalkine (pg/mL)	28.0 (9.02; 71.7)	29.3 (9.82; 74.3)	0.24
IFN-γ (pg/mL)	6.75 (1.65; 21.5)	7.82 (1.63; 22.0)	0.002
IL-1β (pg/mL)	0.98 (0.20; 3.74)	1.08 (0.27; 3.66)	0.033
IL-2 (pg/mL)	0.78 (0.13; 4.11)	0.85 (0.16; 3.91)	0.21
IL-7 (pg/mL)	5.63 (1.34; 18.7)	5.65 (1.12; 18.8)	0.95
IL-8 (pg/mL)	1.74 (0.45; 5.97)	1.91 (0.47; 7.88)	0.048
IL-12 (pg/mL)	1.75 (0.35; 6.40)	1.97 (0.45; 6.72)	0.024
IL-17 A (pg/mL)	3.19 (0.64; 13.5)	3.57 (0.67; 14.1)	0.044
IL-23 (pg/mL)	119 (13.4; 600)	133 (12.9; 668)	0.10
ITAC (pg/mL)	4.70 (1.45; 19.9)	3.67 (1.40; 11.6)	< 0.001
MIP-1α (pg/mL)	9.57 (2.74; 26.3)	10.3 (2.85; 27.0)	0.089
MIP-1β (pg/mL)	7.06 (2.70; 15.6)	7.28 (2.88; 16.4)	0.33
MIP-3α (pg/mL)	2.17 (0.54; 8.12)	1.90 (0.48; 6.61)	0.008
TNF-α (pg/mL)	1.61 (0.41; 5.29)	1.79 (0.49; 5.73)	0.016
<i>Anti-Inflammatory</i>			
IL-4 (pg/mL)	42.62 (7.33; 155)	43.85 (7.92; 154)	0.61
IL-5 (pg/mL)	0.89 (0.20; 3.88)	1.02 (0.26; 3.99)	0.012
IL-10 (pg/mL)	4.38 (0.89; 21.1)	5.42 (1.14; 21.2)	< 0.001
IL-13 (pg/mL)	3.88 (0.58; 23.2)	5.04 (0.69; 30.3)	< 0.001
<i>Pro- and Anti-Inflammatory</i>			
IL-6 (pg/mL)	1.81 (0.25; 9.84)	2.35 (0.30; 12.8)	< 0.001
IL-21 (pg/mL)	1.34 (0.21; 5.53)	1.49 (0.26; 6.53)	0.074
GM-CSF (pg/mL)	7.23 (1.22; 32.5)	8.47 (1.22; 38.1)	0.010
<i>Pro-to-Anti Inflammatory Ratios</i>			
IL-6 to IL-10	0.41 (0.10; 2.03)	0.43 (0.12; 2.02)	0.39
IL-1β to IL-10	0.22 (0.07; 0.73)	0.19 (0.07; 0.52)	0.001
TNF-α to IL-10	0.37 (0.17; 0.98)	0.33 (0.15; 1.01)	< 0.001
CRP to IL-10	0.23 (0.01; 3.80)	0.14 (0.01; 2.40)	< 0.001
MIP-1α to IL-10	2.13 (0.71; 7.72)	1.82 (0.59; 5.76)	< 0.001
ITAC to IL-4	0.11 (0.02; 0.90)	0.08 (0.02; 0.67)	< 0.001
ITAC to IL-5	5.33 (1.10; 32.5)	3.60 (0.79; 17.7)	< 0.001
ITAC to IL-10	1.08 (0.27; 6.65)	0.68 (0.21; 3.12)	< 0.001
ITAC to IL-13	1.22 (0.17; 9.92)	0.73 (0.10; 5.66)	< 0.001
<b>Biochemical Markers and White Blood Cell Counts</b>			
Total Cholesterol (mmol/L)	3.47 ± 0.97	4.04 ± 1.33	< 0.001
HDL-C (mmol/L)	1.14 ± 0.38	1.17 ± 0.46	0.28
LDL-C (mmol/L)	2.07 (0.99; 3.71)	2.45 (1.20; 4.42)	< 0.001
Triglycerides (mmol/L)	0.64 (0.31; 1.37)	0.80 (0.33; 2.11)	< 0.001
Glucose (mmol/L)	3.94 ± 1.03	4.25 ± 1.09	< 0.001
eGFR (ml/min/1.73 m <sup>2</sup> )	118 ± 14.5	106 ± 16.1	< 0.001
White blood cell counts (x10 <sup>9</sup> /L)	5.21 (3.10; 8.40)	5.79 (3.80; 9.36)	< 0.001
Neutrophils (x10 <sup>9</sup> /L)	2.43 (1.03; 5.49)	2.93 (1.35; 5.95)	< 0.001
Lymphocytes (x10 <sup>9</sup> /L)	2.02 (1.26; 3.24)	1.98 (1.29; 3.01)	0.26
Monocytes (x10 <sup>9</sup> /L)	0.30 (0.14; 0.57)	0.42 (0.20; 0.79)	< 0.001
Eosinophils (x10 <sup>9</sup> /L)	0.14 (0.05; 0.41)	0.15 (0.06; 0.39)	0.008
Basophils (x10 <sup>9</sup> /L)	0.04 (0.01; 0.11)	0.04 (0.02; 0.10)	0.013
<b>Health Behaviours</b>			

(continued on next page)

Table 1 (continued)

	Black (n = 599)	White (n = 590)	P
Serum cotinine (ng/ml)	4.04 (1.00; 341)	3.22 (1.00; 308)	0.081
Self-Reported Tobacco use n (%)	154 (25.5)	132 (22.3)	0.18
$\gamma$ -glutamyltransferase (U/L)	22.2 (8.40; 66.2)	14.8 (5.40; 46.6)	< 0.001
Self-Reported Alcohol use, n (%)	333 (55.8)	330 (55.7)	0.99
Hormonal Contraceptive Use, n (% of women)	143 (47.2)	130 (41.9)	0.19

Abbreviations: SBP, Systolic blood pressure; DBP, Diastolic blood pressure; BMI, Body mass index; HDL-C High density lipoprotein cholesterol; LDL-C, Low density lipoprotein cholesterol. Bold values indicate  $P < 0.05$ . Data presented as mean  $\pm$  SD; or geometric mean 95C.I. Granulocyte-macrophage colony-stimulating factor (GM-CSF), Interferon gamma (IFN- $\gamma$ ), Interleukin 1 beta (IL-1 $\beta$ ), Interleukin 2 (IL-2), Interleukin 4 (IL-4), Interleukin 5 (IL-5), Interleukin 6 (IL-6), Interleukin 7 (IL-7), Interleukin 8 (IL-8), Interleukin 10 (IL-10), Interleukin 12 (IL-12), Interleukin 13 (IL-13), Interleukin 17A (IL-17A), Interleukin 21 (IL-21), Interleukin 23 (IL-23), Interferon-inducible T-cell alpha chemoattractant (ITAC), Macrophage inflammatory protein 1- $\alpha$  (MIP-1 $\alpha$ ), Macrophage inflammatory protein 1- $\beta$  (MIP-1 $\beta$ ), Macrophage inflammatory protein 3- $\alpha$  (MIP-3 $\alpha$ ) and Tumour Necrosis Factor Alpha (TNF $\alpha$ ).

white groups with similar mid-level socio-economic status, the original profiles remained robust, suggesting heritability.

#### 4.2. Relationship with blood pressure

Our motivation for this ethnic comparative study was to identify the involvement of specific inflammatory mediators as a possible explanation for the high prevalence of hypertension in black populations [58]. Our analyses yielded no clear findings, with no individual mediator or pattern associating with a range of clinic, central and ambulatory blood pressure measures. Since at this early stage in life there are multiple factors that may dominate physiological variances in blood pressure –

such as differences in renin-angiotensin-aldosterone profiles [58], arterial stiffness [59], and physical activity [60] – blood pressure may not be a measure sensitive enough to show small scale, early inflammatory changes in young otherwise healthy individuals. It may thus be useful to focus on more sensitive markers of early cardiovascular changes such as arterial stiffness, the microvasculature [61], and endothelial function [62].

In addition to the relationship seen with blood pressure, inflammatory mediators are also associated with other disease states. It has been shown that IL-1 $\beta$ , IL-6, IL-17A and TNF- $\alpha$  are implicated in the development of atherosclerosis [63,64], while IL-10 is inversely associated [65]. More research is required regarding detailed inflammatory

Table 2

A comparison of cytokine concentrations between black and white individuals, adjusted for age, sex and waist circumference.

	Black (n = 599)	White (n = 590)	p	Difference: Black minus White
<b>Inflammatory Markers</b>				
<i>Pro-Inflammatory</i>				
CRP (mg/L)	1.16 (1.05; 1.29)	0.67 (0.61; 0.75)	< 0.001	0.49
Fractalkine (pg/mL)	27.9 (26.4; 29.3)	29.5 (28.1; 31.1)	0.12	-1.60
IFN- $\gamma$ (pg/mL)	6.68 (6.25; 7.14)	7.93 (7.40; 8.47)	0.001	-1.25
IL-1 $\beta$ (pg/mL)	0.97 (0.91; 1.04)	1.09 (1.02; 1.17)	0.021	-0.12
IL-2 (pg/mL)	0.77 (0.71; 0.85)	0.86 (0.78; 0.93)	0.12	-0.09
IL-7 (pg/mL)	5.62 (5.25; 6.01)	5.66 (5.28; 6.07)	0.86	-0.04
IL-8 (pg/mL)	1.72 (1.61; 1.84)	1.93 (1.81; 2.07)	0.015	-0.21
IL-12 (pg/mL)	1.74 (1.62; 1.87)	1.98 (1.85; 2.13)	0.013	-0.24
IL-17 A (pg/mL)	3.16 (2.92; 3.40)	3.61 (3.34; 3.90)	0.016	-0.45
IL-23 (pg/mL)	118 (107; 130)	135 (122; 149)	0.059	-17.0
ITAC (pg/mL)	4.70 (4.42; 5.00)	3.67 (3.45; 3.90)	< 0.001	1.03
MIP-1 $\alpha$ (pg/mL)	9.51 (8.95; 10.1)	10.4 (9.75; 11.0)	0.051	-0.89
MIP-1 $\beta$ (pg/mL)	7.24 (6.71; 7.35)	7.31 (7.00; 7.66)	0.20	-0.07
MIP-3 $\alpha$ (pg/mL)	2.15 (2.01; 2.31)	1.91 (1.79; 2.06)	0.022	0.24
TNF- $\alpha$ (pg/mL)	1.59 (1.50; 1.70)	1.80 (1.69; 1.92)	0.008	-0.21
<i>Anti-Inflammatory</i>				
IL-4 (pg/mL)	42.5 (39.4; 45.9)	44.2 (40.1; 47.8)	0.49	-1.70
IL-5 (pg/mL)	0.88 (0.82; 0.95)	1.03 (0.96; 1.11)	0.004	-0.15
IL-10 (pg/mL)	4.32 (4.00; 4.66)	5.48 (5.08; 5.92)	< 0.001	-1.16
IL-13 (pg/mL)	3.83 (3.48; 4.20)	5.11 (4.65; 5.61)	< 0.001	-1.28
<i>Pro- and Anti-Inflammatory</i>				
IL-6 (pg/mL)	1.79 (1.63; 1.96)	2.38 (2.17; 2.62)	< 0.001	-1.37
IL-21 (pg/mL)	1.32 (1.21; 1.43)	1.51 (1.39; 1.64)	0.024	-0.59
GM-CSF (pg/mL)	7.18 (6.58; 7.82)	8.55 (7.83; 9.33)	0.006	-0.19
<i>Pro-to-Anti Inflammatory Ratios</i>				
IL-6 to IL-10	0.41 (0.38; 0.45)	0.43 (0.40; 0.47)	0.38	-0.02
IL-1 $\beta$ to IL-10	0.22 (0.21; 0.23)	0.19 (0.18; 0.20)	0.001	0.03
TNF- $\alpha$ to IL-10	0.37 (0.36; 0.39)	0.33 (0.32; 0.35)	< 0.001	0.04
CRP to IL-10	0.27 (0.24; 0.31)	0.12 (0.11; 0.14)	< 0.001	0.15
MIP-1 $\alpha$ to IL-10	2.14 (2.01; 2.29)	1.81 (1.70; 1.93)	< 0.001	0.33
ITAC to IL-4	0.11 (0.10; 0.12)	0.08 (0.08; 0.09)	< 0.001	0.03
ITAC to IL-5	5.38 (4.98; 5.82)	3.57 (3.30; 3.86)	< 0.001	1.81
ITAC to IL-10	1.10 (1.02; 1.18)	0.67 (0.62; 0.72)	< 0.001	0.43
ITAC to IL-13	1.24 (1.12; 1.36)	0.77 (0.65; 0.79)	< 0.001	0.47

Bold values indicate  $P < 0.05$ .

Normotensive status determined using 24-hour ambulatory blood pressure.

	Total		NT		HT		M		F		Mid SES	
	B	W	B	W	B	W	B	W	B	W	B	W
Black, n	599		536		50		307		307		162	
White, n	590		507		78		311		311		180	
<b>Pro-Inflammatory</b>												
CRP (mg/L)	Red	Orange	Red	Orange			Red	Orange	Red	Orange	Red	Orange
Fractalkine (pg/mL)												
IFN-γ (pg/mL)	Orange	Red	Orange	Red					Orange	Red		
IL-1β (pg/mL)	Orange	Red	Orange	Red								
IL-2 (pg/mL)												
IL-7 (pg/mL)												
IL-8 (pg/mL)	Orange	Red										
IL-12 (pg/mL)	Orange	Red	Orange	Red								
IL-17 A (pg/mL)	Orange	Red	Orange	Red								
IL-23 (pg/mL)												
ITAC (pg/mL)	Red	Orange	Red	Orange	Red	Orange	Red	Orange	Red	Orange	Red	Orange
MIP-1α (pg/mL)			Orange	Red								
MIP-1β (pg/mL)												
MIP-3α (pg/mL)	Red	Orange	Red	Orange					Red	Orange		
TNF-α (pg/mL)	Orange	Red	Orange	Red								
<b>Anti-Inflammatory</b>												
IL-4 (pg/mL)												
IL-5 (pg/mL)	Purple	Purple	Purple	Purple			Purple	Purple				
IL-10 (pg/mL)	Purple	Purple	Purple	Purple			Purple	Purple	Purple	Purple		
IL-13 (pg/mL)	Purple	Purple	Purple	Purple			Purple	Purple				
<b>Pro- and Anti-Inflammatory</b>												
IL-6 (pg/mL)	Orange	Red	Orange	Red	Orange	Red	Orange	Red	Orange	Red		
IL-21 (pg/mL)	Orange	Red	Orange	Red								
GM-CSF (pg/mL)	Orange	Red	Orange	Red			Orange	Red				
<b>Pro-to-Anti Inflammatory Ratios</b>												
IL-6 to IL-10												
IL-1β to IL-10	Dark Blue	Dark Blue	Dark Blue	Dark Blue			Dark Blue	Dark Blue	Dark Blue	Dark Blue		
TNF-α to IL-10	Dark Blue	Dark Blue	Dark Blue	Dark Blue			Dark Blue	Dark Blue	Dark Blue	Dark Blue		
CRP to IL-10	Dark Blue	Dark Blue	Dark Blue	Dark Blue			Dark Blue	Dark Blue	Dark Blue	Dark Blue		
MIP-1α to IL-10	Dark Blue	Dark Blue	Dark Blue	Dark Blue			Dark Blue	Dark Blue	Dark Blue	Dark Blue		
ITAC to IL-4	Dark Blue	Dark Blue	Dark Blue	Dark Blue			Dark Blue	Dark Blue	Dark Blue	Dark Blue		
ITAC to IL-5	Dark Blue	Dark Blue	Dark Blue	Dark Blue			Dark Blue	Dark Blue	Dark Blue	Dark Blue		
ITAC to IL-10	Dark Blue	Dark Blue	Dark Blue	Dark Blue			Dark Blue	Dark Blue	Dark Blue	Dark Blue		
ITAC to IL-13	Dark Blue	Dark Blue	Dark Blue	Dark Blue			Dark Blue	Dark Blue	Dark Blue	Dark Blue		


Fig. 1. Comparison of cytokines between black and white individuals. Cytokine concentrations that differ between black and white participants are indicated in colour (P < 0.05). A darker shade indicates a higher value. Adjusted for: age, sex, waist circumference. Based on Tables 2 and II-VI. Black (B), White (W), Men (M), Women (F), Normotensive (NT), Hypertensive (HT), Middle Socio-economic Status (Mid SES).

mediators in the development of CVD in black and white populations.

Our study results should be interpreted within the framework of its strengths and limitations. Participants were screened prior to participation using strict exclusion criteria for conditions that may affect the results. The absence of pre-existing chronic diseases afforded us the opportunity to investigate the underlying physiology in adults without influence from pathology. A further strength of our study is the inclusion of a wide range of pro- and anti-inflammatory mediators as well as our large sample size. Mediator concentrations were established using a high-sensitivity kit which allowed for detection even at low levels. In terms of limitations, the black group had a greater proportion of individuals with low socio-economic status, allowing for potential socio-

economic bias. However, sensitivity analyses were performed to address this and yielded no changes in our main results. Additionally, this study uses cross-sectional data.

In conclusion, the black and white ethnic groups each consistently presented with unique inflammatory mediator patterns regardless of blood pressure, sex or socio-economic status. Despite a higher pro-to-anti-inflammatory status of the young black adults, there was no association with blood pressure in the black or white groups. Whether these ethnic specific patterns will relate to future disease development, needs to be established.



**Fig. 2.** Multiple regression analyses showing the relationship between cytokine concentrations and 24-hour Systolic Blood Pressure in black and white adults, respectively. Adjusted for: sex, socio-economic status, waist circumference, total cholesterol, glucose, gamma glutamyltransferase, cotinine, estimated glomerular filtration rate, activity energy expenditure.

**CRedit authorship contribution statement**

**Simone H. Crouch:** Conceptualization, Methodology, Validation, Formal analysis, Investigation, Data curation, Writing - original draft, Writing - review & editing, Visualization. **Shani Botha-Le Roux:** Conceptualization, Methodology, Validation, Investigation, Writing - review & editing. **Christian Delles:** Validation, Resources, Writing - review & editing, Funding acquisition. **Lesley A. Graham:** Validation, Formal analysis, Investigation, Writing - review & editing. **Aletta E. Schutte:** Conceptualization, Methodology, Validation, Investigation, Resources, Writing - review & editing, Funding acquisition.

**Declaration of Competing Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**Acknowledgements**


The authors are grateful to all individuals participating voluntarily in the study. The dedication of the support and research staff as well as students at the Hypertension Research and Training Clinic at the North-West University. Merck’s Donald Innes and Robert Hardcastle are also duly acknowledged.

**Sources of Funding**

The research funded in this manuscript is part of an ongoing research project financially supported by the South African Medical Research Council (SAMRC) with funds from National Treasury under its Economic Competitiveness and Support Package; the South African Research Chairs Initiative (SARChI) of the Department of Science and Technology and National Research Foundation (NRF) of South Africa (GUN 86895); SAMRC with funds received from the South African National Department of Health, GlaxoSmithKline R&D (Africa Non-Communicable Disease Open Lab grant), the UK Medical Research Council and with funds from the UK Government’s Newton Fund; as well as corporate social investment grants from Pfizer (South Africa), Boehringer-Ingelheim (South Africa), Novartis (South Africa), the Medi Clinic Hospital Group (South Africa) and in kind contributions of Roche Diagnostics (South Africa). CD is also supported by the British Heart Foundation (Centre of Research Excellence Awards RE/13/5/30177 and RE/18/6/34217).

**Disclosures**

Any opinion, findings, and conclusions or recommendations expressed in this material are those of the authors, and therefore, the NRF does not accept any liability in this regard.



**Fig. 3.** Multiple regression analyses showing the relationship between cytokine concentrations and central systolic blood pressure in black and white adults, respectively. Adjusted for: sex, socio-economic status, waist circumference, total cholesterol, glucose, gamma glutamyltransferase, cotinine, estimated glomerular filtration rate, activity energy expenditure.

## Appendix A. Supplementary material

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.cyto.2019.154894>.

## References

- [1] J.-P. Bastard, M. Maachi, C. Lagathu, M.J. Kim, M. Caron, H. Vidal, J. Capeau, B. Feve, Recent advances in the relationship between obesity, inflammation, and insulin resistance, *Eur. Cytokine Netw.* 17 (1) (2006) 4–12.
- [2] S.I. Grivnenkov, F.R. Greten, M. Karin, Immunity, inflammation, and cancer, *Cell* 140 (6) (2010) 883–899, <https://doi.org/10.1016/j.cell.2010.01.025>.
- [3] F.L. Heppner, R.M. Ransohoff, B. Becher, Immune attack: the role of inflammation in Alzheimer disease, *Nat. Rev. Neurosci.* 16 (6) (2015) 358, <https://doi.org/10.1038/nrn3880>.
- [4] K.H. Simons, A. de Jong, J.W. Jukema, M.R. de Vries, R. Arens, P.H.A. Quax, T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword, *Nat. Rev. Cardiol.* 16 (2019) 325–343, <https://doi.org/10.1038/s41569-019-0164-7>.
- [5] T.A. Pearson, G.A. Mensah, R.W. Alexander, J.L. Anderson, R.O. Cannon, M. Criqui, Y.Y. Fadl, S.P. Fortmann, Y. Hong, G.L. Myers, Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association, *Circulation* 107 (3) (2003) 499–511, <https://doi.org/10.1161/01.CIR.0000052939.59093.45>.
- [6] P. Libby, Inflammation and cardiovascular disease mechanisms, *Am J Clin. Nutr.* 83 (2) (2006) 456S–460S, <https://doi.org/10.1093/ajcn/83.2.456S>.
- [7] P.H. Black, L.D. Garbutt, Stress, inflammation and cardiovascular disease, *J. Psychosom. Res.* 52 (1) (2002) 1–23, [https://doi.org/10.1016/S0022-3999\(01\)00302-6](https://doi.org/10.1016/S0022-3999(01)00302-6).
- [8] P.M. Ridker, M. Cushman, M.J. Stampfer, R.P. Tracy, C.H. Hennekens, Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men, *N. Engl. J. Med.* 336 (14) (1997) 973–979, <https://doi.org/10.1056/NEJM199704033361401>.
- [9] A. Bellasi, L. Di Lullo, B. Di Iorio, Vascular inflammation: a call for a specific and sensitive biomarker? *Elsevier* 271 (2018) 235–236, <https://doi.org/10.1016/j.atherosclerosis.2018.02.018>.
- [10] P. Pauletto, M. Rattazzi, Inflammation and hypertension: the search for a link, *Nephrol. Dial. Transplant.* 21 (4) (2006) 850–853, <https://doi.org/10.1093/ndt/gfl019>.
- [11] J.-M. Fernandez-Real, M. Vayreda, C. Richart, C. Gutierrez, M. Broch, J. Vendrell, Ricart W. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women, *J. Clin. Endocrinol. Metab.* 86 (3) (2001) 1154–1159, <https://doi.org/10.1210/jcem.86.3.7305>.
- [12] W.G. McMaster, A. Kirabo, M.S. Madhur, D.G. Harrison, Inflammation, immunity, and hypertensive end-organ damage, *Circ. Res.* 116 (6) (2015) 1022–1033, <https://doi.org/10.1161/CIRCRESAHA.116.303697>.
- [13] D.G. Harrison, T.J. Guzik, H.E. Lob, M.S. Madhur, P.J. Marvar, S.R. Thabet, A. Vinh, C.M. Weyand, Inflammation, immunity, and hypertension, *Hypertension* 57 (2) (2011) 132–140, <https://doi.org/10.1161/HYPERTENSIONAHA.110.163576>.
- [14] E. Sochet, D. Noone, M. Grattan, C. Slorach, R. Moineddin, Y. Elia, F.H. Mahmud, D.B. Dunger, N. Dalton, D. Cherney, Relationship between serum inflammatory markers and vascular function in a cohort of adolescents with type 1 diabetes, *Cytokine* 99 (2017) 233–239, <https://doi.org/10.1016/j.cyto.2017.07.013>.
- [15] S.C. Harwani, Macrophages under pressure: the role of macrophage polarization in hypertension, *Transl. Res.* 191 (2018) 45–63, <https://doi.org/10.1016/j.trsl.2017.10.011>.
- [16] D.J. Ross, R.M. Strieter, M.C. Fishbein, A. Ardehali, J.A. Belperio, Type I immune response cytokine–chemokine cascade is associated with pulmonary arterial hypertension, *J. Heart Lung Transplant.* 31 (8) (2012) 865–873, <https://doi.org/10.1016/j.healun.2012.04.008>.
- [17] J.-M. Zhang, J. An, Cytokines, inflammation and pain, *Int. Anaesthesiol. Clin.* 45 (2) (2007) 27, <https://doi.org/10.1097/AIA.0b013e318034194e>.
- [18] J. Mayet, N. Chapman, C.K.-C. Li, M. Shahi, N.R. Poulter, P.S. Sever, R.A. Foale, S.A.M. Thom, Ethnic differences in the hypertensive heart and 24-hour blood pressure profile, *Hypertension* 31 (5) (1998) 1190–1194, <https://doi.org/10.1161/01.HYP.31.5.1190>.
- [19] D.S. Minor, M.R. Wofford, D.W. Jones, Racial and ethnic differences in

- hypertension, *Curr. Atheroscler. Rep.* 10 (2) (2008) 121–127.
- [20] L. Gafane, R. Schutte, J. Van Rooyen, A. Schutte, Plasma renin and cardiovascular responses to the cold pressor test differ in black and white populations: The SABPA study, *J. Hum. Hypertens.* 30 (5) (2016) 346, <https://doi.org/10.1038/jhh.2015.88>.
- [21] J. Lindhorst, N. Alexander, J. Blignaut, B. Rayner, Differences in hypertension between blacks and whites: an overview, *Cardiovasc. J. Afr.* 18 (4) (2007) 241.
- [22] J.R. Sowers, M.B. Zemel, P. Zemel, F. Beck, M.F. Walsh, E.T. Zawada, Salt sensitivity in blacks. Salt intake and natriuretic substances, *Hypertension* 12 (5) (1988) 485–490, <https://doi.org/10.1161/01.HYP.12.5.485>.
- [23] A.E. Schutte, A. Myburgh, M.H. Olsen, J. Eugen-Olsen, R. Schutte, Exploring soluble urokinase plasminogen activator receptor and its relationship with arterial stiffness in a bi-ethnic population: the SAfrEIC-study, *Thromb Res.* 130 (2) (2012) 273–277, <https://doi.org/10.1016/j.thromres.2011.10.034>.
- [24] A. Schutte, D. Van Vuuren, J. Van Rooyen, H. Huisman, R. Schutte, L. Malan, N. Malan, Inflammation, obesity and cardiovascular function in African and Caucasian women from South Africa: the POWIRS study, *J. Hum. Hypertens.* 20 (11) (2006) 850, <https://doi.org/10.1038/sj.jhh.1002065>.
- [25] O. Mwantembe, M.-C. Gaillard, M. Barkhuizen, V. Pillay, S.D. Berry, J.B. Dewar, E. Song, Ethnic differences in allelic associations of the interleukin-1 gene cluster in South African patients with inflammatory bowel disease (IBD) and in control individuals, *Immunogenetics* 52 (3–4) (2001) 249–254, <https://doi.org/10.1007/s002510000265>.
- [26] M.S. Elkind, J. Cheng, B. Boden-Albala, T. Rundek, J. Thomas, H. Chen, L.E. Rabbani, R.L. Sacco, Tumor necrosis factor receptor levels are associated with carotid atherosclerosis, *Stroke* 33 (1) (2002) 31–38, <https://doi.org/10.1161/hs0102.100531>.
- [27] J.M. Albandar, A.M. DeNardin, M.R. Adesanya, D.M. Winn, S.R. Diehl, Associations of serum concentrations of IgG, IgA, IgM and interleukin-1 $\beta$  with early-onset periodontitis classification and race, *J. Clin. Periodontol.* 29 (5) (2002) 421–426, <https://doi.org/10.1034/j.1600-051X.2002.290506.x>.
- [28] L. Kalra, C. Rambaran, P. Chowienczyk, D. Goss, I. Hambleton, J. Ritter, A. Shah, R. Wilks, T. Forrester, Ethnic differences in arterial responses and inflammatory markers in Afro-Caribbean and Caucasian subjects, *Arterioscler. Thromb. Vascular Biol.* 25 (11) (2005) 2362–2367, <https://doi.org/10.1161/01.ATV.0000183887.76087.6a>.
- [29] M. Miller, F. Cappuccio, Ethnicity and inflammatory pathways-implications for vascular disease, vascular risk and therapeutic intervention, *Curr. Med. Chem.* 14 (13) (2007) 1409–1425, <https://doi.org/10.2174/092986707780831131>.
- [30] A.H. Heald, S.G. Anderson, F. Ivson, I. Laing, J.M. Gibson, K. Cruickshank, C-reactive protein and the insulin-like growth factor (IGF)-system in relation to risk of cardiovascular disease in different ethnic groups, *Atherosclerosis* 170 (1) (2003) 79–86, [https://doi.org/10.1016/S0021-9150\(03\)00235-1](https://doi.org/10.1016/S0021-9150(03)00235-1).
- [31] S. Hong, P.J. Mills, J.S. Loreda, K.A. Adler, J.E. Dimsdale, The association between interleukin-6, sleep, and demographic characteristics, *Brain Behav. Immun.* 19 (2) (2005) 165–172, <https://doi.org/10.1016/j.bbi.2004.07.008>.
- [32] M. Maritz, C.M. Fourie, J.M. Van Rooyen, S.J. Moss, A.E. Schutte, Large artery stiffness is associated with gamma-glutamyltransferase in young, healthy adults: the African-PREDICT study, *J. Am. Soc. Hypertens.* 10 (10) (2016) pp. 772–781. e771 10.1016/j.jash.2016.07.006.
- [33] A.E. Schutte, P.N. Gona, C. Delles, A.S. Uys, A. Burger, C.M. Mels, R. Kruger, W. Smith, C.M. Fourie, S. Botha, The African prospective study on the early detection and identification of cardiovascular disease and hypertension (African-PREDICT): design, recruitment and initial examination, *Eur. J. Prev. Cardiol* (2019), <https://doi.org/10.1177/2047487318822354>.
- [34] B.K. Patro, K. Jeyashree, P.K. Gupta, Kuppuswamy's socioeconomic status scale 2010—the need for periodic revision, *Indian J. Pediatr.* 79 (3) (2012) 395–396, <https://doi.org/10.1007/s12098-011-0517-7>.
- [35] J. Hypertension 27 (3) (2009) 461–467, <https://doi.org/10.1097/HJH.0b013e3283220ea4>.
- [36] I.B. Wilkinson, J.R. Cockcroft, D.J. Webb, Pulse wave analysis and arterial stiffness, *J. Cardiovasc. Pharmacol.* 32 (1998) S33–S37.
- [37] B. Williams, G. Mancia, W. Spiering, E. Agabiti Rosei, M. Azizi, M. Burnier, D.L. Clement, A. Coca, G. De Simone, A. Dominiczak, 2018 ESC/ESH Guidelines for the management of arterial hypertension, *Eur. Heart J.* 39 (33) (2018) 3021–3104 10.1093/eurheartj/ehy339.
- [38] H.E. van Deventer, J.A. George, J.E. Paiker, P.J. Becker, L.J. Katz, Estimating glomerular filtration rate in black South Africans by use of the modification of diet in renal disease and Cockcroft-Gault equations, *Clin. Chem.* 54 (7) (2008) 1197–1202, <https://doi.org/10.1373/clinchem.2007.099085>.
- [39] T. Seape, V. Gounden, H.E. van Deventer, G.P. Candy, J.A. George, Cystatin C and creatinine-based equations in the assessment of renal function in HIV-positive patients prior to commencing highly active antiretroviral therapy, *Ann. Clin. Biochem.* 53 (1) (2016) 58–66, <https://doi.org/10.1177/0004563215579695>.
- [40] T. Kilic, D. Ural, E. Ural, Z. Yumuk, A. Agacdiken, T. Sahin, G. Kahraman, G. Kozdag, A. Vural, B. Komsuoglu, Relation between proinflammatory to anti-inflammatory cytokine ratios and long-term prognosis in patients with non-ST elevation acute coronary syndrome, *Heart.* 92 (8) (2006) 1041–1046, <https://doi.org/10.1136/hrt.2005.080382>.
- [41] C.A. Gogos, E. Drosou, H.P. Bassaris, A. Skoutelis, Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options, *J. Infect. Dis.* 181 (1) (2000) 176–180, <https://doi.org/10.1086/315214>.
- [42] E.S. Ford, W.H. Giles, G.L. Myers, N. Rifai, P.M. Ridker, D.M. Mannino, C-reactive protein concentration distribution among US children and young adults: findings from the National Health and Nutrition Examination Survey, 1999–2000, *Clin. Chem.* 49 (8) (2003) 1353–1357, <https://doi.org/10.1373/49.8.1353>.
- [43] B. Chamarthi, G.H. Williams, V. Ricchiuti, N. Srikumar, P.N. Hopkins, J.M. Luther, X. Jeunemaitre, A. Thomas, Inflammation and hypertension: the interplay of interleukin-6, dietary sodium, and the renin–angiotensin system in humans, *Am. J. Hypertens.* 24 (10) (2011) 1143–1148, <https://doi.org/10.1038/ajh.2011.113>.
- [44] M. Hamer, L. Malan, A. Schutte, H. Huisman, J. Van Rooyen, R. Schutte, C. Fourie, N. Malan, Y. Seedat, Conventional and behavioral risk factors explain differences in sub-clinical vascular disease between black and Caucasian South Africans: the SABPA study, *Atherosclerosis* 215 (1) (2011) 237–242, <https://doi.org/10.1016/j.atherosclerosis.2010.12.015>.
- [45] K. Mörs, O. Braun, N. Wagner, B. Auner, M. Voth, P. Störmann, S. Wutzler, I. Marzi, B. Relja, Influence of gender on systemic IL-6 levels, complication rates and outcome after major trauma, *Immunobiology* 221 (8) (2016) 904–910, <https://doi.org/10.1016/j.imbio.2016.03.005>.
- [46] H. Zhu, N.K. Pollock, I. Kotak, B. Gutin, X. Wang, J. Bhagatwala, S. Parikh, G.A. Harshfield, Y. Dong, Dietary sodium, adiposity, and inflammation in healthy adolescents, *Pediatrics* 133 (3) (2014) 635–642, <https://doi.org/10.1542/peds.2013-1794>.
- [47] S.C. Hoffmann, E.M. Stanley, E.D. Cox, B.S. DiMercurio, D.E. Koziol, D.M. Harlan, A.D. Kirk, P.J. Blair, Ethnicity greatly influences cytokine gene polymorphism distribution, *Am. J. Transplant.* 2 (6) (2002) 560–567, <https://doi.org/10.1034/j.1600-6143.2002.20611.x>.
- [48] E.D. Cox, S.C. Hoffmann, B.S. DiMercurio, R.A. Wesley, D.M. Harlan, A.D. Kirk, P.J. Blair, cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of Interleukin-2 and Interleukin-61, *Transplantation* 72 (4) (2001) 720–726, <https://doi.org/10.1097/00007890-200108270-00027>.
- [49] T.W. McDade, M. Hoke, J.B. Borja, L.S. Adair, C. Kuzawa, Do environments in infancy moderate the association between stress and inflammation in adulthood? Initial evidence from a birth cohort in the Philippines, *Brain Behav. Immun.* 31 (2013) 23–30, <https://doi.org/10.1016/j.bbi.2012.08.010>.
- [50] Y. Arnson, Y. Shoenfeld, H. Amital, Effects of tobacco smoke on immunity, inflammation and autoimmunity, *J. Autoimmun.* 34 (3) (2010) J258–J265, <https://doi.org/10.1016/j.jaut.2009.12.003>.
- [51] S. Stewart, Alcohol and inflammation: a possible mechanism for protection against ischemic heart disease, *Nutr. Metab. Cardiovasc. Dis.* 12 (3) (2002) 148–151.
- [52] AVENA study group, Inflammatory proteins are related to total and abdominal adiposity in a healthy adolescent population: the AVENA Study, *Am. J. Clin. Nutr.* 84 (3) (2006) 505–512, <https://doi.org/10.1093/ajcn/84.3.505>.
- [53] J.L. Reid, D. Hammond, P. Driezen, Socio-economic status and smoking in Canada, 1999–2006: has there been any progress on disparities in tobacco use? *Can. J. Public Health* 101 (1) (2010) 73–78, <https://doi.org/10.1007/BF03405567>.
- [54] T. Huckle, R.Q. You, S. Casswell, Socio-economic status predicts drinking patterns but not alcohol-related consequences independently, *Addiction* 105 (7) (2010) 1192–1202.
- [55] T. Sørensen, Socio-economic aspects of obesity: causes or effects? *Int. J. Obes. Relat. Metab. Disord.* 19 (1995) S6–S8, <https://doi.org/10.1111/j.1360-0443.2010.02931.x>.
- [56] S. Stringhini, G.D. Batty, P. Bovet, M.J. Shipley, M.G. Marmot, M. Kumari, A.G. Tabak, M. Kivimäki, Association of life-course socioeconomic status with chronic inflammation and type 2 diabetes risk: the Whitehall II prospective cohort study, *PLoS Med.* 10 (7) (2013) e1001479, <https://doi.org/10.1371/journal.pmed.1001479>.
- [57] R. Pollitt, J. Kaufman, K. Rose, A.V. Diez-Roux, D. Zeng, G. Heiss, Cumulative life course and adult socioeconomic status and markers of inflammation in adulthood, *J. Epidemiol. Community Health* 62 (6) (2008) 484–491, <https://doi.org/10.1136/jech.2006.054106>.
- [58] B.L. Rayner, J.D. Spence, Hypertension in blacks: insights from Africa, *J. Hypertens.* 35 (2) (2017) 234–239, <https://doi.org/10.1097/HJH.0000000000001171>.
- [59] A.E. Schutte, H.W. Huisman, R. Schutte, J.M. Van Rooyen, L. Malan, N.T. Malan, M. Reimann, Arterial stiffness profiles: investigating various sections of the arterial tree of African and Caucasian people, *Clin. Exp. Hypertens.* 33 (8) (2011) 511–517 10.3109/10641963.2011.561897.
- [60] A. Chin, X. Xin, J. He, Exercise Lowers Blood Pressure, *Ann. Intern. Med.* 136 (2002) 493–503.
- [61] R. Klein, B.E. Klein, M.D. Knudtson, T.Y. Wong, M.Y. Tsai, Are inflammatory factors related to retinal vessel caliber? the Beaver Dam eye study, *Arch. Ophthalmol.* 124 (1) (2006) 87–94, <https://doi.org/10.1001/archoph.124.1.87>.
- [62] D. Tousoulis, M. Charakida, C. Stefanadis, Endothelial function and inflammation in coronary artery disease, *Postgrad. Med. J.* 84 (993) (2008) 368–371 <http://dx.doi.org/10.1136/hrt.2005.066936>.
- [63] J. Moriya, Critical roles of inflammation in atherosclerosis, *J. Cardiol.* 73 (1) (2019) 22–27, <https://doi.org/10.1016/j.jicc.2018.05.010>.
- [64] Q. Gao, Y. Jiang, T. Ma, F. Zhu, F. Gao, P. Zhang, C. Guo, Q. Wang, X. Wang, C. Ma, A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice, *J. Immunol.* 185 (10) (2010) 5820–5827, <https://doi.org/10.4049/jimmunol.1000116>.
- [65] L. Fourman, C. Saylor, L. Cheru, K. Fitch, S. Looby, K. Keller, J. Robinson, U. Hoffmann, M. Lu, T. Burdo, Anti-inflammatory interleukin-10 is inversely related to coronary atherosclerosis in people with Hiv, *J. Infect. Dis.* (2019), <https://doi.org/10.1093/infdis/jiz254>.